Journal of Pharmaceutical and Biomedical Analysis · 2018 · 76 citations · 21 references
Life SciencesImmunologyPharmacologyClinical ImmunologyImmunopathologyMonoclonal AntibodiesAntibody CharacterizationAntigen Detection AssaysCerebrospinal Fluid BiomarkersEnzyme-linked Immunosorbent AssayImmunoassay AnalysisImmunoassay DevelopmentCerebrospinal Fluid AnalysisCerebrospinal Fluid Antibody TestingCerebrospinal Fluid CytokinesCerebrospinal Fluid Inflammatory BiomarkersCerebrospinal Fluid Inflammatory MediatorsImmunoassay MethodologySerum Biomarkers
21
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14